CN115944087A - Probiotic composition for relieving alcoholism and protecting liver, product and application thereof - Google Patents
Probiotic composition for relieving alcoholism and protecting liver, product and application thereof Download PDFInfo
- Publication number
- CN115944087A CN115944087A CN202310085055.6A CN202310085055A CN115944087A CN 115944087 A CN115944087 A CN 115944087A CN 202310085055 A CN202310085055 A CN 202310085055A CN 115944087 A CN115944087 A CN 115944087A
- Authority
- CN
- China
- Prior art keywords
- product
- liver
- probiotic composition
- prebiotics
- mass ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 67
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 210000004185 liver Anatomy 0.000 title claims abstract description 46
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 44
- 208000007848 Alcoholism Diseases 0.000 title abstract description 21
- 201000007930 alcohol dependence Diseases 0.000 title abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 29
- 239000002131 composite material Substances 0.000 claims abstract description 23
- 239000000419 plant extract Substances 0.000 claims abstract description 23
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 23
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 14
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 14
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 14
- 240000008042 Zea mays Species 0.000 claims abstract description 14
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 14
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 14
- 235000005822 corn Nutrition 0.000 claims abstract description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 14
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims abstract description 13
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims abstract description 13
- 229920001202 Inulin Polymers 0.000 claims abstract description 13
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 13
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 13
- 241001468157 Lactobacillus johnsonii Species 0.000 claims abstract description 13
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 13
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000010903 husk Substances 0.000 claims abstract description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 13
- 229940029339 inulin Drugs 0.000 claims abstract description 13
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 13
- 229960002675 xylitol Drugs 0.000 claims abstract description 13
- 235000010447 xylitol Nutrition 0.000 claims abstract description 13
- 239000000811 xylitol Substances 0.000 claims abstract description 13
- 244000134552 Plantago ovata Species 0.000 claims abstract description 9
- 235000003421 Plantago ovata Nutrition 0.000 claims abstract description 9
- 239000009223 Psyllium Substances 0.000 claims abstract description 4
- 229940070687 psyllium Drugs 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims description 14
- 206010019133 Hangover Diseases 0.000 claims description 10
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 5
- 241001127637 Plantago Species 0.000 claims description 5
- 235000015266 Plantago major Nutrition 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 230000002443 hepatoprotective effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 51
- 230000000694 effects Effects 0.000 abstract description 22
- 230000006378 damage Effects 0.000 abstract description 9
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 230000002496 gastric effect Effects 0.000 abstract description 4
- 230000035622 drinking Effects 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000006185 dispersion Substances 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 17
- 241000700159 Rattus Species 0.000 description 11
- 206010067125 Liver injury Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 231100000753 hepatic injury Toxicity 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000002075 anti-alcohol Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 241000628997 Flos Species 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 241000195634 Dunaliella Species 0.000 description 1
- 241000195633 Dunaliella salina Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 235000008584 Hovenia dulcis Nutrition 0.000 description 1
- 244000010000 Hovenia dulcis Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a probiotic composition for relieving alcoholism and protecting liver, a product and an application thereof, wherein the probiotic composition comprises composite probiotics, prebiotics and plant extracts, the composite probiotics comprises lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14, the prebiotics comprise xylitol, isomaltulose and inulin, and the plant extracts comprise corn oligopeptide powder, psyllium husk powder and sodium hyaluronate. The invention can promote the rapid dispersion of alcohol, reduce the damage of alcohol to liver and achieve the aim of sobering up. Meanwhile, the probiotic composition can regulate intestinal flora disorder, recover gastrointestinal permeability, relieve the damage of alcohol to organisms and livers and play a role in protecting the livers. Before drinking or after long-term use, the product can reduce the damage of alcohol to the liver and has better effect of relieving alcoholism and protecting the liver.
Description
Technical Field
The invention relates to the technical field of health care and health preservation, and particularly relates to a probiotic composition for relieving alcoholism and protecting liver, a product and application thereof.
Background
The liver is the main organ for metabolizing alcohol, after drinking, alcohol is catalyzed by Alcohol Dehydrogenase (ADH) in the liver to generate acetaldehyde, and the acetaldehyde is further oxidized into nontoxic acetic acid by the acetaldehyde dehydrogenase (ALDH) in liver mitochondria to finally generate carbon dioxide and energy. However, the speed of alcohol metabolism by the liver is slow, alcohol has cytotoxicity, the liver is difficult to metabolize rapidly due to excessive drinking once, lipid on the surface of a liver cell membrane is over oxidized due to alcohol accumulation in the liver, the liver cell membrane is damaged, the structures such as microtubules, mitochondria and the like in the liver cell are damaged due to further development, the metabolism in the cell is disordered, and the cytotoxic metabolite acetaldehyde is generated, so that the liver cell is swollen and necrotic. Therefore, excessive drinking beyond the limit of alcohol metabolism easily causes damage to the liver and decline of liver function, and poses a great threat to human health.
With the gradual enhancement of health and safety awareness of consumers, people have a gradually increasing demand for anti-alcohol and liver-protecting products, for example, CN103750320A discloses a product with anti-alcohol and liver-protecting functions, which comprises the following components: ganoderma, fructus Schisandrae chinensis, semen Hoveniae, flos Puerariae Lobatae, flos Buddlejae and fructus Jujubae. The invention has good functions of relieving alcoholism and protecting liver. CN106492110A discloses an anti-hangover composition, which comprises the following components: maca extract, kudzu root extract, turmeric extract and hovenia dulcis thunb extract. The invention can promote the rapid absorption and decomposition of alcohol in vivo, is beneficial to the rapid sobering up of alcohol pickers, prevents hangover and has better effect of protecting liver. CN108126123A discloses an anti-alcoholism and liver-protecting composition, which is prepared from the following raw material components: semen Hoveniae, flos Puerariae Lobatae, poria, atractylodis rhizoma, rhizoma Phragmitis, fructus Ligustri Lucidi, herba Menthae and Dunaliella, wherein semen Hoveniae and flos Puerariae Lobatae have effects of relieving hangover and inducing diuresis; the tuckahoe and the atractylodes macrocephala have the effects of tonifying spleen and qi, promoting diuresis and calming heart and are ministerial; the mint has the effects of soothing liver and resolving depression, the reed rhizome has the effects of clearing lung and promoting fluid production, the glossy privet fruit has the effects of tonifying liver and kidney, and the seven medicines are used as adjuvant medicines, mainly have the effects of tonifying spleen and removing dampness, and have the coordination of the functions of the heart, the liver, the spleen, the lung and the kidney; the addition of Dunaliella salina can improve immunity and nourish cell. The invention can play the roles of relieving alcoholism, protecting liver and inducing diuresis, can promote the discharge of alcohol from urine, and simultaneously can resist oxidation, strengthen stomach and protect stomach, thereby reducing the harm of alcohol to human body.
The liver is closely related to the intestinal tract, and the damage and the pathological changes of the liver are often related to the disturbance of the intestinal flora. In recent years, studies have suggested that intestinal flora changes due to alcohol consumption may also be involved in the development of liver damage caused by alcohol consumption, which can be treated and ameliorated by regulating the intestinal flora changes caused by alcohol consumption by the consumption of probiotics. Based on the above, the probiotic composition for relieving alcoholism and protecting liver is developed.
Disclosure of Invention
The invention provides a probiotic composition for relieving alcoholism and protecting liver, a product and an application thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a probiotic composition for relieving alcoholism and protecting liver, which comprises composite probiotics, prebiotics and plant extracts, wherein the composite probiotics comprise lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14, the prebiotics comprise xylitol, isomaltulose and inulin, and the plant extracts comprise corn oligopeptide powder, psyllium husk powder and sodium hyaluronate.
In certain embodiments, the probiotic composition comprises the following components in parts by weight: 18-20 parts of composite probiotics, 2-6 parts of prebiotics and 3-5 parts of plant extracts.
In certain embodiments, the mass ratio of lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14 in the composite probiotic is 1-3; preferably 2.
In certain embodiments, the prebiotic has a mass ratio of xylitol, isomaltulose, and inulin from 3-8; further preferably 4-7; preferably, the ratio is 5.
In certain embodiments, the mass ratio of corn oligopeptide powder, psyllium husk powder and sodium hyaluronate in the plant extract is 8-12; preferably 10.
The probiotic composition contains more than 700 hundred million viable bacteria (CFU) per serving.
The probiotic composition provided by the invention can generate a synergistic effect by combining the composite probiotics, the prebiotics and the plant extract, and achieves an unexpected technical effect on the aspects of dispelling the effects of alcohol and protecting the liver.
On the other hand, the invention provides the application of the probiotic composition in preparing a product for relieving alcoholism and protecting liver.
On the other hand, the invention also provides an anti-alcohol liver-protecting product which comprises the probiotic composition for anti-alcohol liver protection.
In certain embodiments, the anti-hangover and liver-protecting product is a food or health food.
In some embodiments, the anti-alcohol and liver-protecting product further comprises an auxiliary material acceptable for food or health food.
In certain embodiments, the anti-hangover and hepatoprotective product is a pharmaceutical product.
In some embodiments, the anti-alcoholism liver-protection product further comprises medically acceptable auxiliary materials.
In certain embodiments, the pharmaceutical product is in the form of a tablet, powder, granule, or capsule.
The invention has the beneficial effects that:
the probiotic composition for relieving alcoholism and protecting liver can promote the rapid dispersion of alcohol, reduce the damage of the alcohol to the liver and achieve the aim of sobering up. Meanwhile, the probiotic composition can regulate intestinal flora disorder, recover gastrointestinal permeability, relieve the damage of alcohol to organisms and livers and play a role in protecting the livers.
Before drinking or after long-term use, the product can reduce the damage of alcohol to the liver and has better effect of relieving alcoholism and protecting the liver.
Drawings
Fig. 1 is a graph showing the effect of probiotic compositions provided in examples and comparative examples of the present invention on the ethanol content in rat blood.
Fig. 2 is a graph showing the effect of probiotic compositions provided in examples and comparative examples of the present invention on MDA levels in the liver.
Fig. 3 is a graph of the effect of probiotic compositions provided in examples and comparative examples of the present invention on GSH levels in the liver.
Fig. 4 is a graph showing the effect of probiotic compositions provided in examples and comparative examples of the present invention on TG levels in the liver.
Detailed Description
The following examples are only given to aid the understanding of the method of the invention and its core idea. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention. The following description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The raw materials used in the present invention are all common commercial products unless otherwise specified. Wherein, the molecular weight of 99 percent of the corn oligopeptide powder is distributed between 200 Da and 400Da, the content of the Plantago ovata forsk husk powder is 98 percent, the fineness of the product is 800 meshes, the water content is less than or equal to 7 percent, and the sodium hyaluronate is food grade with the purity of 99 percent.
Example 1
The probiotic composition for relieving alcoholism and protecting liver comprises the following components in parts by weight: 18 parts of composite probiotics, 2 parts of prebiotics and 3 parts of plant extract;
wherein the mass ratio of lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14 in the composite probiotics is 1;
the mass ratio of xylitol, isomaltulose and inulin in the prebiotics is 3;
the mass ratio of corn oligopeptide powder, plantain seed husk powder and sodium hyaluronate in the plant extract is 8;
an adjuvant comprising: 5 parts of edible essence.
Mixing the above materials, making into granule, and packaging into bags, 2g each.
Example 2
The probiotic composition for relieving alcoholism and protecting liver comprises the following components in parts by weight: 20 parts of composite probiotics, 6 parts of prebiotics and 5 parts of plant extract;
wherein the mass ratio of lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14 in the composite probiotics is 3;
the mass ratio of xylitol, isomaltulose and inulin in the prebiotics is 8;
the mass ratio of the corn oligopeptide powder, the Plantago ovata seed husk powder and the sodium hyaluronate in the plant extract is 12.
The auxiliary materials comprise: 5 parts of edible essence.
Mixing the above materials, making into granule, and packaging into bags, 2g each.
Example 3
The probiotic composition for relieving alcoholism and protecting liver comprises the following components in parts by weight: 19 parts of composite probiotics, 4 parts of prebiotics and 4 parts of plant extracts;
wherein the mass ratio of lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14 in the composite probiotics is 2;
the mass ratio of xylitol, isomaltulose and inulin in the prebiotics is 5;
the mass ratio of the corn oligopeptide powder, the Plantago ovata seed husk powder and the sodium hyaluronate in the plant extract is 10.
The auxiliary materials comprise: 5 parts of edible essence.
Mixing the above materials, making into granule, and packaging into bags, 2g each.
Example 4
The probiotic composition for relieving alcoholism and protecting liver comprises the following components in parts by weight: 19 parts of composite probiotics, 4 parts of prebiotics and 4 parts of plant extracts;
wherein the mass ratio of lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14 in the composite probiotics is 2;
the mass ratio of xylitol, isomaltulose and inulin in the prebiotics is 7;
the mass ratio of the corn oligopeptide powder, the plantain seed husk powder and the sodium hyaluronate in the plant extract is 11.
The auxiliary materials comprise: 5 parts of edible essence.
Mixing the above materials, making into granule, and packaging into bags with 2g each bag.
Example 5
The probiotic composition for relieving alcoholism and protecting liver comprises the following components in parts by weight: 19 parts of composite probiotics, 4 parts of prebiotics and 4 parts of plant extracts;
wherein the mass ratio of lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14 in the composite probiotics is (3);
the mass ratio of xylitol, isomaltulose and inulin in the prebiotics is 4;
the mass ratio of the corn oligopeptide powder, the Plantago ovata seed husk powder and the sodium hyaluronate in the plant extract is 9.
The auxiliary materials comprise: 5 parts of edible essence.
Mixing the above materials, making into granule, and packaging into bags with 2g each bag.
Comparative example 1
The comparative example differs from example 3 in that: the composite probiotics comprise lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14 which have different mass ratios.
Wherein the mass ratio of lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14 is 5.
Comparative example 2
This comparative example differs from example 3 in that: the prebiotics are different in the mass ratio of xylitol, isomaltulose and inulin.
Wherein the mass ratio of the xylitol, the isomaltulose and the inulin is 1.
Comparative example 3
This comparative example differs from example 3 in that: the plant extracts are different in the mass ratio of corn oligopeptide powder, plantain seed shell powder and sodium hyaluronate.
Wherein the mass ratio of the corn oligopeptide powder, the plantain seed husk powder and the sodium hyaluronate is 5.
Comparative example 4
CN111249371A is a composition prepared by the specific embodiment for relieving alcoholism and protecting liver.
The probiotic compositions prepared in examples 1-5 and comparative examples 1-3 above contained a viable bacteria Count (CFU) of 700 hundred million or more per serving.
The function experiment of the composition for relieving alcoholism and protecting liver provided by the invention is as follows.
(1) Determination of ethanol content in rat blood
Experimental animals: SPF grade Wistar rats weighing 120-150g were randomly divided into experimental groups (examples 1-5 and comparative examples 1-4, 9 groups) and control groups of 8 rats each.
The experimental method comprises the following steps: mice in the experimental group and the control group are fed with free diet and drinking water for 7 days in an adaptive manner. The rats in the experimental group are respectively gavaged with the probiotic composition prepared in the examples 1-5 and the comparative examples 1-4, the gavage dose is 2g/kg BW per day, the rats in the control group are gavaged with physiological saline with the same volume as the rats in the control group, after the gavage of each group is finished for 30min, the rats are respectively gavaged with 50% ethanol, and the gavage dose is 0.018ml/g body weight. Collecting tail blood 30min, 60min, 90min and 120min after wine filling, and detecting ethanol content in blood with gas chromatograph. The results of the experiment are shown in table 1 and fig. 1.
Table 1 shows that, after the administration groups 1 to 5 of the probiotic composition provided in examples 1 to 5 of the present invention are perfused for 30min, 60min, 90min and 120min, the content of ethanol in blood is lower than that of the control group, and is significantly different (P is less than 0.05) compared with the control group, which indicates that the probiotic composition provided in examples 1 to 5 of the present invention can promote ethanol degradation and effectively reduce the content of ethanol in blood. The administration groups 3-5 of the probiotic composition provided by the gavage examples 3-5 have very significant difference (P < 0.01) compared with the control group, and the probiotic composition provided by the examples 3-5 has better effect of promoting ethanol degradation.
After 30min, 60min, 90min and 120min of alcohol filling, the content of ethanol in blood of the administration groups 6-8 is slightly lower than that of the control group, but compared with the control group, the content has no significant difference (P is more than 0.05), and the probiotic composition provided by the comparative examples 1-3 has no effect of promoting ethanol degradation compared with the control group under the condition of the same dosage.
TABLE 1
Note: p < 0.05, P < 0.01 compared to control.
Meanwhile, as shown in fig. 1, the peak areas of the ethanol content curves of the administration groups 1 to 9 were smaller than those of the control group, in which the peak areas of the ethanol content curves of the administration groups 3, 4 and 5 were relatively small and the peak area of the ethanol content curve of the administration group 3 was the smallest.
2. Auxiliary protection effect on alcoholic liver injury
The modeling method comprises the following steps: referring to nineteen in technical specifications for health food detection and evaluation (2003 edition), a second scheme in an inspection method for auxiliary protection of chemical liver injury: and (5) modeling an alcoholic liver injury model.
Experimental animals: SPF grade SD rats weighing 180-210g.
The experimental method comprises the following steps: the SD rats are randomly divided into an experimental group 1-9, a model group and a control group, and the mice are fed with free diet and water for 7 days in an adaptive manner. Experimental groups 1-9 rats were gavaged with the probiotic compositions prepared in examples 1-5 and comparative examples 1-4, respectively, at a gavage dose of 2g/kg BW/day, and the model group and the control group were gavaged with an equal volume of physiological saline for continuous gavage for 7 days. After the last intragastric administration for 1h, the experimental groups 1-9 and the model group are intragastric administered with 12ml/kgBW of 50% ethanol, after fasting for 16h, the rats are killed, and the contents of MDA, GSH and TG are detected. The results of the experiments are shown in FIGS. 2-4.
As can be seen from FIGS. 2 to 4, MDA, GSH and TG in the model group have significant differences (# P < 0.05) compared with the control group, which indicates that the modeling of the alcoholic liver injury model of the invention is successful. Meanwhile, the MDA, GSH and TG of the experimental groups 3-5 of the probiotic composition provided by the gastric perfusion examples 3, 4 and 5 have significant difference (P < 0.05) compared with the model group, which shows that the probiotic composition provided by the invention has auxiliary protection effect on alcoholic liver injury, wherein the GSH and TG of the experimental group 1 have significant difference (P < 0.05) compared with the model group, and the TG of the experimental group 2 has significant difference (P < 0.05) compared with the model group, which shows that the probiotic composition provided by the examples 1 and 2 of the invention has certain auxiliary protection effect on alcoholic liver injury.
Compared with a model group, MDA, GSH and TG of the experimental group 6-9 have no significant difference (P is more than 0.05), and the probiotic compositions provided by the comparative examples 1-4 have no auxiliary protection effect on alcoholic liver injury under the gastric lavage dosage of the invention.
Claims (10)
1. The probiotic composition is characterized by comprising composite probiotics, prebiotics and plant extracts, wherein the composite probiotics comprise lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14, the prebiotics comprise xylitol, isomaltulose and inulin, and the plant extracts comprise corn oligopeptide powder, psyllium husk powder and sodium hyaluronate.
2. The probiotic composition according to claim 1, characterized by comprising the following components in parts by weight: 18-20 parts of composite probiotics, 2-6 parts of prebiotics and 3-5 parts of plant extracts.
3. The probiotic composition according to claim 2, characterized by comprising the following technical scheme:
(1) The mass ratio of lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14 in the composite probiotics is 1-3;
(2) The mass ratio of xylitol, isomaltulose and inulin in the prebiotics is 3-8;
(3) The mass ratio of the corn oligopeptide powder, the plantain seed husk powder and the sodium hyaluronate in the plant extract is 8-12.
4. The probiotic composition according to claim 2, characterized in that the mass ratio of lactobacillus johnsonii LJ-G55, bifidobacterium adolescentis BQ-G66, lactobacillus acidophilus LA-G80 and lactobacillus rhamnosus Lr-G14 in the composite probiotic is 2; the mass ratio of xylitol, isomaltulose and inulin in the prebiotics is 5; the mass ratio of the corn oligopeptide powder, the Plantago ovata seed husk powder and the sodium hyaluronate in the plant extract is 10.
5. Use of the probiotic composition of any one of claims 1 to 4 for the preparation of a product for alleviating hangover and protecting liver.
6. An anti-hangover and hepatoprotective product comprising the probiotic composition of any one of claims 1 to 4.
7. The product of claim 6, wherein the product is a food or health food.
8. The product of claim 6, further comprising an auxiliary material acceptable for food or health food.
9. The anti-hangover and hepatoprotective product of claim 6, wherein the anti-hangover and hepatoprotective product is a drug.
10. The anti-hangover and hepatoprotective product of claim 9, further comprising a pharmaceutically acceptable excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310085055.6A CN115944087B (en) | 2023-01-16 | 2023-01-16 | Probiotic composition and product for dispelling effects of alcohol and protecting liver and application of probiotic composition and product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310085055.6A CN115944087B (en) | 2023-01-16 | 2023-01-16 | Probiotic composition and product for dispelling effects of alcohol and protecting liver and application of probiotic composition and product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115944087A true CN115944087A (en) | 2023-04-11 |
| CN115944087B CN115944087B (en) | 2024-07-23 |
Family
ID=87287642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310085055.6A Active CN115944087B (en) | 2023-01-16 | 2023-01-16 | Probiotic composition and product for dispelling effects of alcohol and protecting liver and application of probiotic composition and product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115944087B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060233774A1 (en) * | 2005-04-19 | 2006-10-19 | Korea Yakult Co., Ltd | Composition for the improvement of liver function, the reduction of serum ethanol level and antioxidant activity enhancement |
| CN105796662A (en) * | 2016-03-31 | 2016-07-27 | 河南蓝图制药有限公司 | Psyllium seed husk powder and inulin composition |
| CN106072657A (en) * | 2016-06-08 | 2016-11-09 | 天津隆顺榕发展制药有限公司 | Probiotic composition and preparation method thereof |
| CN107568736A (en) * | 2017-07-04 | 2018-01-12 | 劲膳美食品股份有限公司 | Dealcoholic sobering-up medical science formula food |
| CN108208853A (en) * | 2018-01-04 | 2018-06-29 | 山东凤凰生物有限公司 | A kind of relieving alcoholism and protecting liver probiotics oligopeptide compound formulation and preparation method |
| CN111249371A (en) * | 2018-11-30 | 2020-06-09 | 内蒙古伊利实业集团股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and product |
| CN112137112A (en) * | 2020-09-21 | 2020-12-29 | 杭州迈亚塔生物科技有限公司 | Composite food for dispelling effects of alcohol and protecting liver and preparation method thereof |
| CN112569323A (en) * | 2020-12-31 | 2021-03-30 | 上海交大昂立股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and application thereof |
| CN114468046A (en) * | 2020-11-13 | 2022-05-13 | 江苏万邦医药科技有限公司 | Composition with effects of dispelling effects of alcohol, protecting liver and protecting stomach |
-
2023
- 2023-01-16 CN CN202310085055.6A patent/CN115944087B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060233774A1 (en) * | 2005-04-19 | 2006-10-19 | Korea Yakult Co., Ltd | Composition for the improvement of liver function, the reduction of serum ethanol level and antioxidant activity enhancement |
| CN105796662A (en) * | 2016-03-31 | 2016-07-27 | 河南蓝图制药有限公司 | Psyllium seed husk powder and inulin composition |
| CN106072657A (en) * | 2016-06-08 | 2016-11-09 | 天津隆顺榕发展制药有限公司 | Probiotic composition and preparation method thereof |
| CN107568736A (en) * | 2017-07-04 | 2018-01-12 | 劲膳美食品股份有限公司 | Dealcoholic sobering-up medical science formula food |
| CN108208853A (en) * | 2018-01-04 | 2018-06-29 | 山东凤凰生物有限公司 | A kind of relieving alcoholism and protecting liver probiotics oligopeptide compound formulation and preparation method |
| CN111249371A (en) * | 2018-11-30 | 2020-06-09 | 内蒙古伊利实业集团股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and product |
| CN111249347A (en) * | 2018-11-30 | 2020-06-09 | 内蒙古伊利实业集团股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and product |
| CN112137112A (en) * | 2020-09-21 | 2020-12-29 | 杭州迈亚塔生物科技有限公司 | Composite food for dispelling effects of alcohol and protecting liver and preparation method thereof |
| CN114468046A (en) * | 2020-11-13 | 2022-05-13 | 江苏万邦医药科技有限公司 | Composition with effects of dispelling effects of alcohol, protecting liver and protecting stomach |
| CN112569323A (en) * | 2020-12-31 | 2021-03-30 | 上海交大昂立股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| SU-JIN JUNG等: "Regulation of Alcohol and Acetaldehyde Metabolism by a Mixture of Lactobacillus and Bifidobacterium Species in Human", NUTRIENTS, vol. 13, no. 6, pages 1 - 13 * |
| 田露露等: "乳杆菌和双歧杆菌对碳水化合物体外利用的比较研究", 《乳业科学与技术》, vol. 45, no. 1, pages 7 - 14 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115944087B (en) | 2024-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104856003A (en) | Non-full nutritional formula food for patients with diabetes | |
| CN104435748A (en) | Dendrobium officinale compound preparation as well as preparation method and application of dendrobium officinale compound preparation | |
| CN105614851A (en) | Medical formula food for hepatic encephalopathy | |
| CN102727530A (en) | Combination and application of probiotics and related prebiotics | |
| CN112006137A (en) | Spleen-tonifying and stomach-nourishing Su-radish tea and preparation method thereof | |
| CN106333022A (en) | Compound cordyceps sinensis and ginseng instant tea and preparation method thereof | |
| CN104171204A (en) | Tea for alleviating colorectal cancer | |
| CN105380265A (en) | Liver cancer medical formula food | |
| CN104855968A (en) | Liver cancer non-complete nutrition formula food | |
| CN107412665B (en) | It is a kind of that there is Chinese medicine composition for relieving the effect of alcohol, preventing alcoholic liver injury and its preparation method and application | |
| CN108042683A (en) | A kind of integration of drinking and medicinal herbs product of anti-haze clearing lung-heat | |
| CN115944087B (en) | Probiotic composition and product for dispelling effects of alcohol and protecting liver and application of probiotic composition and product | |
| CN104013733A (en) | Chitosan composition for prevention and treatment of chemical liver injury and preparation method thereof | |
| CN108785583B (en) | Cough-relieving pharmaceutical composition and preparation method and application thereof | |
| CN103961614A (en) | Traditional Chinese medicine composition for treating respiratory system diseases as well as preparation method and application thereof | |
| CN111109596A (en) | Health product for enhancing immunity and preparation method thereof | |
| CN105395702A (en) | Composition with hangover alleviating, liver protecting and anti-fatigue efficacy and application thereof | |
| CN104146267B (en) | The full nutritional formulas of lupus erythematosus | |
| CN102552806A (en) | Fat-burning dredging particles and preparation method thereof | |
| CN114796197A (en) | Composition for dispelling effects of alcohol and protecting liver and preparation thereof | |
| CN105639251A (en) | Chafing dish seasoning capable of reducing internal heat and nourishing yin | |
| CN1985944A (en) | Chinese medicine composition for treating cutaneous pruritus, rubella and other diseases | |
| CN103977127B (en) | A kind of Chinese medicine composition for the treatment of infantile asthma and preparation method thereof | |
| CN106387210A (en) | Tea bag capable of eliminating dampness and clearing heat and preparation method of tea bag | |
| CN101574464A (en) | Ageing-resisting and immunity-enhancing capsule prepared by multiple pure traditional Chinese drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |